Jubilant Pharmova Limited has informed the Exchange regarding Appointment of Mr. Priyavrat Bhartia as Managing Director of the company w.e.f. Jun 01, 2026.
JUBLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Jubilant Pharmova's Board has approved the re-appointment of Mr. Priyavrat Bhartia as Managing Director and Mr. Arjun Shanker Bhartia as Joint Managing Director for a further 3-year term starting June 1, 2026, pending shareholder approval. Both executives are sons of the company's top leadership—Priyavrat is son of Chairman Shyam Sunder Bhartia, while Arjun is son of Co-Chairman Hari Shanker Bhartia. This represents a continuation of the Bhartia family's long-standing control over company management. Both have been in their current roles since June 2023 and on the Board since 2017.
This announcement indicates stability in company leadership and continuity of the Bhartia family's management control. Shareholders should note this is a routine re-appointment rather than a change in direction. The stock is unlikely to see any significant reaction to this expected development.